MA29836B1 - Proteines de fusion avec l'albumine - Google Patents

Proteines de fusion avec l'albumine

Info

Publication number
MA29836B1
MA29836B1 MA30727A MA30727A MA29836B1 MA 29836 B1 MA29836 B1 MA 29836B1 MA 30727 A MA30727 A MA 30727A MA 30727 A MA30727 A MA 30727A MA 29836 B1 MA29836 B1 MA 29836B1
Authority
MA
Morocco
Prior art keywords
fusion proteins
albumin fusion
albumin
vectors
host cells
Prior art date
Application number
MA30727A
Other languages
English (en)
Inventor
Adam Bell
Paul Moore
Yanggu Shi
David Lafleur
Michael Laird
Craig Rosen
William Haseltine
Douglas Woods
Jason Bock
Mani Subramanian
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of MA29836B1 publication Critical patent/MA29836B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

La présente invention englobe des protéines de fusion d'albumine. Les molécules d'acides nucléiques codant pour les protéines de fusion d'albumine de l'invention sont également englobées par l'invention, de même que les vecteurs contenant ces acides nucléiques, les cellules hôtes transformées avec ces vecteurs d'acides nucléiques, et les procédés de fabrication des protéines de fusion d'albumine de l'invention et utilisant ces acides nucléiques, vecteurs, et/ou cellules hôtes. De plus, la présente invention comprend des compositions pharmaceutiques comprenant les protéines de fusion d'albumine et les procédés de traitement, de prévention, ou d'amélioration de maladies, troubles pathologies utilisant les protéines de fusion d'albumine de l'invention.
MA30727A 2005-08-12 2008-03-07 Proteines de fusion avec l'albumine MA29836B1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US70752105P 2005-08-12 2005-08-12
US71238605P 2005-08-31 2005-08-31
US73272405P 2005-11-03 2005-11-03
US77691406P 2006-02-28 2006-02-28
US78136106P 2006-03-13 2006-03-13
US81018206P 2006-06-02 2006-06-02
US81368206P 2006-06-15 2006-06-15

Publications (1)

Publication Number Publication Date
MA29836B1 true MA29836B1 (fr) 2008-10-03

Family

ID=37758042

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30727A MA29836B1 (fr) 2005-08-12 2008-03-07 Proteines de fusion avec l'albumine

Country Status (13)

Country Link
EP (1) EP1924596A4 (fr)
JP (1) JP2009504157A (fr)
KR (1) KR20080071119A (fr)
AU (1) AU2006280312A1 (fr)
BR (1) BRPI0614761A2 (fr)
CA (1) CA2618476A1 (fr)
EC (1) ECSP088262A (fr)
IL (1) IL189246A0 (fr)
MA (1) MA29836B1 (fr)
MX (1) MX2008001865A (fr)
NO (1) NO20081233L (fr)
TN (1) TNSN08064A1 (fr)
WO (1) WO2007021494A2 (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
EP1276849A4 (fr) 2000-04-12 2004-06-09 Human Genome Sciences Inc Proteines fusionnees a de l'albumine
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
EP2277889B1 (fr) 2001-12-21 2014-07-09 Human Genome Sciences, Inc. Protéines chimériques d'albumine et interféron beta
BRPI0507026A (pt) 2004-02-09 2007-04-17 Human Genome Sciences Inc proteìnas de fusão de albumina
EP1816201A1 (fr) 2006-02-06 2007-08-08 CSL Behring GmbH Facteur de coagulation VIIa modifié ayant une stabilité 'half-life' améliorée
AU2007258609B2 (en) * 2006-06-07 2013-01-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP2068905A4 (fr) * 2006-09-14 2009-12-30 Human Genome Sciences Inc Protéines de fusion d'albumine
US7884184B2 (en) 2007-01-30 2011-02-08 Epivax, Inc. Regulatory T cell epitopes, compositions and uses thereof
JP5685529B2 (ja) 2008-06-13 2015-03-18 プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダＰｒｏｙｅｃｔｏ Ｄｅ Ｂｉｏｍｅｄｉｃｉｎａ Ｃｉｍａ， Ｓ．Ｌ． 生物学的活性を有する化合物の投与のための複合体
EP2387420A2 (fr) 2009-01-16 2011-11-23 Teva Pharmaceutical Industries Limited Nouvelles formulations stables de protéine de fusion d'albumine humaine recombinante et facteur humain de stimulation de colonie de granulocytes
JP5936112B2 (ja) 2009-02-11 2016-06-15 アルブミディクス アクティーゼルスカブ アルブミン変異体及び複合体
KR20100100254A (ko) * 2009-03-05 2010-09-15 (주)바이오큐어팜 인간 혈청 알부민-팀프-2 융합 단백질과 항암제를 포함하는암의 예방 또는 치료용 조성물
CN102741422B (zh) 2009-08-24 2016-06-08 阿穆尼克斯运营公司 凝血因子ⅶ组合物及其制备和使用方法
CN105567699A (zh) * 2009-10-30 2016-05-11 诺维信生物制药丹麦公司 白蛋白变体
CN106977608A (zh) 2010-04-09 2017-07-25 阿尔布麦狄克斯公司 白蛋白衍生物和变体
US9238080B2 (en) 2010-05-21 2016-01-19 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
CN103402542B (zh) * 2011-02-28 2017-05-03 独立行政法人国立循环器病研究中心 恶性肿瘤转移抑制用药物
US8822417B2 (en) 2011-05-05 2014-09-02 Novozymes Biopharma DIC A/S Albumin variants
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2012170969A2 (fr) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Composés pro-coagulants et leurs procédés d'utilisation
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8853176B2 (en) 2011-10-21 2014-10-07 Abbvie Inc. Methods for treating HCV
GB2515942A (en) 2011-10-21 2015-01-07 Abbvie Inc Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
WO2013075066A2 (fr) 2011-11-18 2013-05-23 Eleven Biotherapeutics, Inc. Protéines ayant une demi-vie et d'autres propriétés améliorées
BR112014017165B1 (pt) 2012-01-12 2023-05-02 Bioverativ Therapeutics Inc Proteína quimérica compreendendo uma proteína de fator viii, composição farmacêutica, e seus usos
JP6256882B2 (ja) 2012-02-15 2018-01-10 アムニクス オペレーティング インコーポレイテッド 第ｖｉｉｉ因子組成物、ならびに組成物の作製方法および用途
JP6383666B2 (ja) 2012-02-15 2018-08-29 バイオベラティブ セラピューティクス インコーポレイテッド 組換え第ｖｉｉｉ因子タンパク質
BR112014018679A2 (pt) 2012-03-16 2017-07-04 Novozymes Biopharma Dk As variantes de albumina
AU2013270683A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Chimeric clotting factors
JP2015521589A (ja) 2012-06-08 2015-07-30 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． プロコアグラント化合物
CN103525695B (zh) * 2012-07-04 2015-05-20 长沙中生众捷生物技术有限公司 便携式肾功能检测系统
SG10201913893XA (en) 2012-07-11 2020-03-30 Bioverativ Therapeutics Inc Factor viii complex with xten and von willebrand factor protein, and uses thereof
WO2014063108A1 (fr) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Procédés d'utilisation d'une dose fixe d'un facteur de coagulation
MX2015005363A (es) 2012-11-08 2015-11-06 Novozymes Biopharma Dk As Variantes de albumina.
EP3889173B1 (fr) 2013-02-15 2023-07-05 Bioverativ Therapeutics Inc. Gène du facteur viii optimisé
EP3318124A3 (fr) 2013-02-16 2018-05-30 Albumedix A/S Modèle pharmacocinétique animal
CA2899089C (fr) 2013-03-15 2021-10-26 Biogen Ma Inc. Preparations contenant un polypeptide du facteur ix
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
EP3048899B1 (fr) 2013-09-25 2021-09-08 Bioverativ Therapeutics Inc. Procédés d'inactivation de virus sur colonne
EP3065769A4 (fr) 2013-11-08 2017-05-31 Biogen MA Inc. Composé de fusion procoagulant
RS63583B1 (sr) 2014-01-10 2022-10-31 Bioverativ Therapeutics Inc Himerni proteini faktora viii i njihova upotreba
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
NZ730563A (en) 2014-10-14 2019-05-31 Halozyme Inc Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
WO2017029407A1 (fr) 2015-08-20 2017-02-23 Albumedix A/S Variants de l'albumine et leurs conjugués
EP3355907B1 (fr) 2015-10-02 2021-01-20 Silver Creek Pharmaceuticals, Inc. Protéines thérapeutiques bispécifiques pour la réparation de tissus
CN105254766B (zh) * 2015-10-26 2018-10-16 中国航天员科研训练中心 机械生长因子MGF E domain肽在调控记忆相关基因和miRNA表达中的应用
DK3411478T3 (da) 2016-02-01 2022-09-12 Bioverativ Therapeutics Inc Optimerede faktor viii-gener
WO2017189978A1 (fr) 2016-04-28 2017-11-02 Emory University Compositions thérapeutiques à base de nucléotides et nucléosides contenant un alcyne et utilisations associées
CN110337590A (zh) 2016-11-04 2019-10-15 奥胡斯大学 以新生儿Fc受体过表达为特征的肿瘤的识别和治疗
IL266972B2 (en) 2016-12-02 2024-04-01 Bioverativ Therapeutics Inc Methods for the treatment of hemophilic arthritis with the help of chimeric blood coagulation factors
BR112019011198A2 (pt) 2016-12-02 2019-12-17 Bioverativ Therapeutics Inc métodos de indução de tolerância imune a fatores de coagulação
EP3562840A1 (fr) 2016-12-16 2019-11-06 Biogen MA Inc. Facteur 11 de différenciation de croissance activé protéolytiquement stabilisé
EA201991768A1 (ru) 2017-01-31 2020-01-22 Байоверетив Терапьютикс Инк. Слитые белки на основе фактора ix и способы их получения и пути применения
MA50141A (fr) * 2017-04-20 2020-07-29 Novo Nordisk As Procédés de purification de protéines de fusion d'albumine
CN111247251A (zh) 2017-08-09 2020-06-05 比奥维拉迪维治疗股份有限公司 核酸分子及其用途
BR112020015228A2 (pt) 2018-02-01 2020-12-29 Bioverativ Therapeutics Inc. Uso de vetores lentivirais que expressam fator viii
EP3833766A1 (fr) 2018-08-09 2021-06-16 Bioverativ Therapeutics Inc. Molécules d'acide nucléique et leurs utilisations pour une thérapie génique non virale
US20200199626A1 (en) 2018-12-06 2020-06-25 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor ix
US20210113634A1 (en) 2019-09-30 2021-04-22 Bioverativ Therapeutics Inc. Lentiviral vector formulations
JPWO2022030580A1 (fr) * 2020-08-06 2022-02-10
WO2024080306A1 (fr) * 2022-10-11 2024-04-18 Ｊｃｒファーマ株式会社 Protéine de fusion d'albumine sérique et de protéine physiologiquement active

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2277889B1 (fr) * 2001-12-21 2014-07-09 Human Genome Sciences, Inc. Protéines chimériques d'albumine et interféron beta
CA2513213C (fr) * 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Proteines hybrides d'albumine
BRPI0507026A (pt) * 2004-02-09 2007-04-17 Human Genome Sciences Inc proteìnas de fusão de albumina
US20060051859A1 (en) * 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs

Also Published As

Publication number Publication date
ECSP088262A (es) 2008-05-30
MX2008001865A (es) 2008-04-15
JP2009504157A (ja) 2009-02-05
NO20081233L (no) 2008-05-09
TNSN08064A1 (en) 2009-07-14
KR20080071119A (ko) 2008-08-01
CA2618476A1 (fr) 2007-02-22
WO2007021494A3 (fr) 2007-07-26
WO2007021494A2 (fr) 2007-02-22
IL189246A0 (en) 2008-08-07
EP1924596A2 (fr) 2008-05-28
AU2006280312A1 (en) 2007-02-22
EP1924596A4 (fr) 2009-07-29
BRPI0614761A2 (pt) 2009-05-19

Similar Documents

Publication Publication Date Title
MA29836B1 (fr) Proteines de fusion avec l'albumine
EP1841426A4 (fr) Carbinamines tertiaires incluant des heterocycles substitues, agissant en tant qu'inhibiteurs de la beta-secretase et utilisees dans le traitement de la maladie d'alzheimer
NO20054769L (no) Substituerte fenylalkansyrer
MX2009002816A (es) Proteinas de fusion de albumina.
MA31862B1 (fr) Anticorps anti-mésothéline et leurs utilisations
EA200870019A1 (ru) Лактамовые соединения и способы их применения
MA30340B1 (fr) Nouveaux composes
WO2004019878A3 (fr) Adzymes et leurs utilisations
BRPI0513959A (pt) anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
DE602005021072D1 (de) Adzyme und deren verwendungen
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
TNSN07063A1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
MA30085B1 (fr) Traitement du diabete de type 2 avec une association d'un inhibiteur de dpiv et de metformine ou d'une thiazolidinedione
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
ATE483692T1 (de) Als beta-sekretase (bace)-hemmer nützliche 2- amino-chinazolinderivate
NO20054957L (no) Subtituerte karboksylsyrer
WO2005077042A3 (fr) Proteines hybrides d'albumine
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
EA200802054A1 (ru) Ингибиторы фермента
BRPI0407662B8 (pt) derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
TW200505418A (en) Phenacyl 2-hydroxy-3-diaminoalkanes
WO2006078576A3 (fr) Inhibiteurs de la $g(b)-secretase d'aminomethyle dans le traitement de la maladie d'alzheimer
MA30041B1 (fr) Immunoglobulines